Phase 1/2Completed
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes
- Sponsor
- Mesoblast, Ltd. (Industry)
- Enrolment
- 30 enrolled
- Conditions
- Diabetic Nephropathy; Type 2 Diabetes
- Interventions
- Mesenchymal Precursor Cells (MPCs); Mesenchymal Precursor Cells (MPCs)
- Ages
- adults, older adults
- Registry
- NCT01843387
From the registry
The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.
Primary outcomes
- The primary objective of the study is to assess the safety and tolerability of MPC therapy